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Background: KLF5 is a basic transcriptional factor that regulates multiple physiopathological processes. Our recent
study showed that deletion of Klf5 in mouse prostate promotes tumorigenesis initiated by the deletion of Pten. While
molecular characterization of Klf5-null tumors suggested that angiogenesis was partially responsible for tumor promotion,
the precise function and mechanism of KLF5 deletion in prostate tumor angiogenesis remain unclear.
Results: Applying histological staining to Pten-null mouse prostates, we observed that deletion of Klf5 significantly
increased the number of microvessels, accompanied by the upregulation of multiple angiogenesis-related genes
based on microarray analysis with MetaCore software. In human umbilical vein endothelial cells (HuVECs), tube
formation and migration, both of which are indicators of angiogenic activities, were decreased by conditioned
media from PC-3 and DU 145 human prostate cancer cells with KLF5 overexpression, but increased by media from
cells with KLF5 knockdown. HIF1α, a key angiogenesis inducer, was upregulated by KLF5 loss at the protein but
not the mRNA level in both mouse tissues and human cell lines, as determined by immunohistochemical staining,
real-time RT-PCR and Western blotting. Consistently, KLF5 loss also upregulated VEGF and PDGF, two pro-angiogenic
mediators of HIF1α function, as analyzed by immunohistochemical staining in mouse tissues and ELISA in conditioned
media. Mechanistically, AKT activity, which caused the accumulation of HIF1α, was increased by KLF5 knockout or
knockdown but decreased by KLF5 overexpression. PI3K/AKT inhibitors consistently abolished the effects of KLF5
knockdown on angiogenic activity, HIF1α accumulation, and VEGF and PDGF expression.
Conclusion: KLF5 loss enhances tumor angiogenesis by attenuating PI3K/AKT signaling and subsequent
accumulation of HIF1α in PTEN deficient prostate tumors.
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Angiogenesis, the process of forming new blood vessels
from pre-existing vessels, is vital for development, tissue
wound healing, and tumor initiation and progression [1].
Tumor angiogenesis is activated by multiple pro-
angiogenic secretory factors including VEGF, PDGF-B,
bFGF and TNF-α, which are all transcriptionally activated
by hypoxia inducible factor 1 (HIF1) [2], composed of* Correspondence: j.dong@emory.edu
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the protein level by the ubiquitin proteasome pathway,
whose activation depends on the oxygen level, or by the
activation of PI3K/AKT and MAPK signaling in a tumor,
which is independent of oxygen level [2,3]. Targeting
angiogenesis has been proposed as a therapeutic approach
in prostate and other types of solid tumors for decades,
and a number of candidate drugs have been tested in clin-
ical trials. However, few of them have been officially ap-
proved for cancer treatment and their success has been
limited [4]. A better understanding of the molecular basis
of angiogenesis should improve the development of anti-
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codes a basic transcription factor expressed in different
tissues to regulate diverse cellular processes [5]. In
tumorigenesis, KLF5 has been shown to play a context-
dependent role. On one hand, its genetic locus is fre-
quently deleted in human cancers [5,6]; a tumor suppres-
sor function has been established in mouse models where
KLF5 expression suppresses tumor growth [7,8] and dele-
tion of Klf5 in mouse prostates promotes tumorigenesis
initiated by the deletion of Pten [9]. On the other hand,
interruption of KLF5 acetylation converts its function
from that of a tumor suppressor to a tumor promoter, and
multiple oncogenic pathways appear to be involved [8].
Recent studies also suggest that KLF5 could regulate
angiogenesis. KLF5 is markedly induced in activated
vascular smooth muscle cells and fibroblasts, deletion of
Klf5 in mice compromises vascular remodeling involv-
ing Pdgf-a [10], and loss of Klf5 in mouse cornea epithe-
lial cells results in abnormal neovascularization with
elevated expression of angiogenesis-related genes
[11,12]. In our recent study [9], we found that deletion
of Klf5 in Pten-null mouse prostates resulted in larger
tumors without lumens and necrosis, which were
present in tumors induced by Pten deletion alone [13]
but with enhanced activation of AKT and ERK, which
are reported to promote tumor angiogenesis [14,15]. It
is thus possible that KLF5 modulates angiogenesis dur-
ing prostatic tumorigenesis.
In this study, we tested whether and how KLF5 regulates
angiogenesis in the context of PTEN loss in prostate can-
cer. We found that in Pten-null mouse prostate tumors,
deletion of Klf5 significantly promoted angiogenesis, and
conditioned media from human prostate cancer cells with
modulated KLF5 expression affected tube formation and
migration of human umbilical vein endothelial cells
(HuVECs). Expression profiling and other analyses dem-
onstrated that Klf5 deletion led to the upregulation of
multiple pro-angiogenic genes and accumulation of
HIF1α, a transcription factor that stimulates angiogenesis.
Additional experiments showed that accumulation of
HIF1α induced by KLF5 loss depended on the activation
of the PI3K/AKT signaling pathway. These findings sug-
gest that KLF5 loss promotes tumor angiogenesis by en-
hancing PI3K/AKT signaling and the subsequent
accumulation of HIF1α in PTEN deficient prostate cancer.
Results
Klf5 deletion promotes angiogenesis initiated by Pten
deletion in mouse prostate tumors
To test whether Klf5 deletion plays a role in tumor
angiogenesis, we first examined H&E stained tissue sec-
tions for the number of intraepithelial blood vessels, in-
dicated by histological appearance and the presence of
red blood cells between wildtype tissues and those withKlf5 deletion. We used dorsal prostate tumors of
8 month old mice for the Pten-null group, and whole
prostate with high grade mPINs of 12 to 18 month old
mice for the Pten hemizygous group. The number of
microvessels was clearly increased by homozygous dele-
tion of Klf5 in both Pten groups (Figure 1A, 1B upper
panels). To more accurately determine the number of
microvessels in mPINs and prostate tumors, we performed
immunohistochemical staining for the Cd31 endothelial
cell marker and counted the number of microvessels indi-
cated by positive Cd31 staining (Figure 1A, B, lower
panels). The density of microvessels, determined by divid-
ing the number of Cd31-marked microvessels by the total
area of epithelial cells, was significantly increased by both
hemizygous and homozygous deletions of Klf5 in the
Pten-null tumors and by Klf5 homozygous deletion in the
Pten-hemizygous group (Figure 1, bar figures). The in-
crease in angiogenesis correlated with the increase in
tumor mass and the decrease in Klf5 expression caused by
Klf5 deletion in the same mice [9]. This result indicates
that Klf5 deletion promotes angiogenesis in both prostate
tumors and mPINs induced by Pten deletion.
Klf5 deletion activates the angiogenesis transcriptional
network and HIF1α in Pten-null mouse prostates
In our recent study, expression profiling and MetaCore
analysis of mouse dorsal prostates at 6 months in the
Pten-null background indicated that the process of blood
morphogenesis is the most enriched upon the deletion
of Klf5 [9], composed of 39 differentially expressed
genes. We searched the PubMed database for articles on
each of the 39 genes, and reviewed these articles to de-
termine whether the genes are pro- or anti-angiogenic.
Among the 39 genes, 33 (84.6%) were reported to pro-
mote, 3 (7.7%) to suppress, and 3 (7.7%) to have unclear
effects on angiogenesis. Twenty six (79%) of the 33 pro-
angiogenic genes were significantly upregulated by Klf5
deletion. The 36 genes with a promoting or repressing
effect are listed in Additional file 1: Table S1, along with
their expression fold changes caused by Klf5 deletion,
and a heatmap of these genes is shown in Figure 2A.
Dysregulation of these genes indicates an enhanced
angiogenesis transcription network resulting from Klf5
deletion.
Based on the process indicative of active angiogenesis,
we attempted to determine whether a specific pathway or
a key transcription factor was activated by Klf5 deletion to
drive the pro-angiogenic phenotype, using the MetaCore
program. Interestingly, HIF1α, an important mediator of
tumor angiogenesis [16], was identified as a key tran-
scription factor (Figure 2B) with p-value 4.2 × 10−147, as
it affected the expression of 115 of the differentially
expressed genes. Among the 115 genes, 49 were identi-
fied as direct transcriptional targets activated by HIF1α,
Figure 1 Klf5 deletion increases blood microvessels in mouse prostate tumors. H&E staining and IHC staining of Cd31 for blood microvessels from prostates
at 8 months for Pten−/− (A) and 12 to 18 months for Pten+/− (B). Black arrows point to microvessels inside prostatic acini. Images at the right upper corner are
higher magnifications of boxed areas. Microvessels were counted in dorsal lobes for Pten−/− prostates and the entire lobes for Pten+/− prostates. The
total area of prostatic epithelia excluding the lumen space inside the acini was measured with ImageJ software. Gene status is indicated at the top of
each panel, and + and – indicate wildtype and deletion of Klf5 or Pten, respectively. Three to 6 mice were used for each group. Microvessel density was
defined by the number of microvessels per mm2. *, P < 0.05; **, P < 0.01; N.S., not statistically significant.
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deletion (Figure 2B), suggesting an activated HIF1α
transcription activity. VEGF and some of its related
molecules are direct targets and functional mediators of
HIF1α in angiogenesis [17,18], so we analyzed mRNA
expression for several molecules of the HIF1α/VEGF
signaling pathway, including Hif1α, Vegf-a, Vegfr1 and
Vegfr2, by real-time RT-PCR using 8 mouse dorsal pros-
tates for each genotype of Klf5 deletion in the Pten-null
background. As shown in Figure 2C, the Hif1α mRNA
level was unchanged, while Vegf-a, Vegfr1 and Vegfr2mRNA levels were all increased by Klf5 homozygous de-
letion. Of these,Vegf-a was not identified by the micro-
array analysis. Klf5 deletion upregulated Pdgf-b, Pdgf-d
and Pdgfrb mRNA expression in the microarray analysis
(Figure 2A), suggesting an activated PDGF signaling
pathway that could play an important role in angiogen-
esis [19]. Pdgf-b is also a transcriptional target of HIF1α
[20] and could also be a functional mediator of HIF1α.
Therefore, we examined mRNA expression of these
PDGF signaling molecules by real-time RT-PCR, and
confirmed the microarray analysis findings that Pdgf-b,
Figure 2 Klf5 deletion dysregulates angiogenesis-related genes and enhances HIF1α transcriptional activity in Pten-null mouse prostates. (A) Heatmap
of genes involved in angiogenesis based on the MetaCore analysis and PubMed publications and that had >1.5 fold change in expression between
wildtype and Klf5-null mouse prostates (4 samples per group, indicated at the top). Genes are clustered by their effects on angiogenesis, with those
promoting and repressing angiogenesis marked as “promote” and “repress”, respectively. Color intensities in the heat map represent log2 values of
expression intensities. The percentage of upregulated or downregulated genes is shown. (B) HIF1α is activated by Klf5 deletion, as indicated by the
upregulation of its direct transcriptional target genes based on MetaCore’s interactome analysis for transcription factors. Different shapes of the nodes
represent functional classifications of genes. Red dots on the upper right corner of each symbol indicate increased expression level, and green lines
indicate positive regulation. (C) Detection of Hif1α/Vegf and Pdgf signaling molecules by real-time RT-PCR in 6-month-old Pten-null mouse dorsal
prostates with indicated Klf5 deletion status. Data for each genotype were from 8 mice.* and **indicate P < 0.05 and P < 0.01, respectively.
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(Figure 2C). Hemizygous deletion of Klf5 had a mild ef-
fect on the expression of these molecules. These results
indicate that Klf5 deletion activates multiple key regula-
tors of angiogenesis.
We also examined protein expression of Hif1α, Vegf,
Pdgf-b and Pdgf-d in prostates with different Klf5 deletion
status by IHC staining. In Pten-null prostates, although
the mRNA expression of Hif1α was not affected by Klf5
deletion (Figure 2), its protein expression was increased in
both the nucleus and the cytoplasm of prostatic cells by
both hemizygous and homozygous deletions of Klf5
(Figure 3A). In addition, almost all cells with Klf5deletion were positive for Hif1α expression in the nu-
cleus (Figure 3A), which indicates an active Hif1α status
[3]. In the context of Pten hemizygous deletion, accu-
mulation of Hif1α was increased upon Klf5 deletion in
prostates of one year old mice, and homozygous dele-
tion of Klf5 also significantly increased the ratio of cells
with positive Hif1α nuclear staining (Figure 3B). For
pro-angiogenic factors Vegf, Pdgf-b and Pdgf-d, whose
mRNA expression was upregulated by Klf5 deletion
(Figure 2A, C), an increase in their protein expression
was also detected in Pten-null prostates with both hemizy-
gous and homozygous deletions of Klf5 (Figure 3C). In
prostates with Pten hemizygous deletion, only homozygous
Figure 3 Klf5 deletion increases protein expression of Hif1α and pro-angiogenic factors. (A, B) IHC staining of Hif1α in mouse prostates at 4 months
for Pten−/− and 12 months for Pten+/−. The numbers of Hif1α-positive cells and total prostatic epithelial cells were counted with ImageJ software for
each mouse. (C, D) Protein expression of pro-angiogenic factors Vegf, Pdgf-d and Pdgf-b as detected by IHC staining with the same mouse tissues
used in panels A and B. Three or 4 mice were used for each group. *, P < 0.05; **, P < 0.01; N.S., not statistically significant.
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(Figure 3D). These results further indicate that Klf5 loss
induces the enhanced expression and activity of Hif1α ac-
companied with augmented expression of pro-angiogenic
factors.
Dysregulation of KLF5 in prostate cancer cells impacts
tube formation and migration of HuVECs
To further test the role of KLF5 in angiogenesis, we de-
termined whether changes in KLF5 expression in humanprostate cancer cells directly modulate endothelial cell
behaviors such as tube formation and migration, both of
which are indicative of angiogenesis. We used PC-3
(PTEN null) and DU 145 (PTEN haploinsufficient) hu-
man prostate cancer cell lines [21] and human umbilical
vein endothelial cells (HuVECs) for the analysis. In vitro
cultured cells eliminate any effects of tumor growth
in vivo, thus providing evidence for a direct effect of
KLF5 on angiogenesis. We first knocked down KLF5
using lentiviruses expressing shRNAs in PC-3 and DU
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mouse model. Using stable cell populations with efficient
knockdown of KLF5, we collected conditioned media
and applied them to HuVECs for tube formation assay,
in which HuVECs formed a tubular network of intercon-
necting branches after 5–7 hours. Knockdown of KLF5
in both PC-3 and DU 145 cell lines significantly in-
creased the cumulative tube length and the number of
tube nodes in HuVECs (Figure 4A). Considering that
both PC-3 and DU 145 cell lines express a relatively
lower level of KLF5 [22,23], we also overexpressed KLF5Figure 4 Expression changes in KLF5 in human prostate cancer cell lines m
B) and transwell assay (C, D) of human umbilical vein endothelial cells (Hu
KLF5 knockdown (A) and ectopic expression (B) mediated by lentiviral infec
ten fields were measured with ImageJ software, and each unit is 100 pixels
serum-free medium. Conditioned media was added to the lower wells, and
stained with crystal violet and counted from 20 fields at 4× with ImageJ so
sh37) (A, C), and Ctrl and KLF5 indicate the pSin vector control and pSin-Kby lentiviral infection in these two cell lines and per-
formed HuVEC tube formation assay with conditioned
media. Consistent with the knockdown result, ectopic
expression of KLF5 significantly inhibited tube formation
in vitro, as indicated by the cumulative tube length and
the number of tube nodes (Figure 4B).
Vascular endothelial cell migration is a critical step
and another indicator of angiogenic ability [24], so we
also performed transwell and wound healing assays to
evaluate the effect of KLF5 dysregulation on the migra-
tion of HuVECs. Conditioned media from both PC-3odulate the angiogenic activities of HuVECs. Tube formation assay (A,
VECs) with conditioned media (CM) from PC-3 and DU 145 cells with
tion. For tube formation assay, tube length and node number from
. For transwell assay, HuVECs were seeded in the upper chamber with
cells migrating to the bottom side of the upper chamber were
ftware. shK1 and shK2 indicate two shRNAs targeting KLF5(sh36 and
LF5 expression construct, respectively (B, D). *, P < 0.05; **, P < 0.01.
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promoted, whereas those from these cells with ectopic ex-
pression of KLF5 significantly inhibited, the migration of
HuVECs, as indicated by the number of cells migrated
through the membrane in the transwell assay (Figure 4C,
D) and the extent of gap in the wound healing assay
(Additional file 2: Figure S1). These in vitro assays pro-
vide another line of evidence for the role of KLF5 in
angiogenesis in PTEN-deficient prostate cancer cells.
KLF5 also regulates the expression of HIF1α and other
pro-angiogenic factors in human prostate cancer cells
Based on our finding that manipulation of KLF5 expres-
sion in human prostate cancer cells affected tube forma-
tion and migration of HuVECs (Figure 4), we further
tested whether manipulation of KLF5 expression also af-
fects the expression of HIF1α and other pro-angiogenic
factors as in mouse tissues. We performed Western blot-
ting to detect HIF1α expression and ELISA to detect the
secretion of VEGF and PDGF-B in prostate cancer cells,
whereas PDGF-D is undetectable by ELISA due to a low
level of expression. As shown in Figure 5A, knockdown of
KLF5 in PC-3 and DU 145 cells by lentiviral shRNA clearly
increased the expression of HIF1α and PDGF-B, although
the expression of VEGF was increased in PC-3 cells
but slightly decreased in DU 145 cells (not statisticallyFigure 5 KLF5 decreases protein expression of HIF1α and secretion of pro-
(A), ectopic expression (B), RNAi-mediated transient knockdown (C), or ade
tected by Western blotting whereas secretory pro-angiogenic factors PDGF
and shK2 indicate 2 lentiviral shRNAs targeting KLF5 (sh36 and sh37), siK re
expressing KLF5. *, P < 0.05; **, P < 0.01; N.S., not statistically significant.significant). Consistently, ectopic expression of KLF5 by
lentiviral infection in the same two cell lines decreased the
expression of HIF1α, VEGF and PDGF-B (Figure 5B). We
also used transient transfection of siRNAs to knock down
KLF5 (Figure 5C) and adenoviral infection to transiently
express KLF5 (Figure 5D) in the two prostate cancer cell
lines, and confirmed that knockdown and overexpression
of KLF5 respectively increased and decreased the expres-
sion of HIF1α (Figure 5C, D).
We also detected mRNA expression of HIF1α, VEGF
and PDGF-B in human prostate cancer cells with altered
KLF5 expression. PDGF-B and VEGF-A mRNA showed
the same trend of change as their protein expression
(Additional file 3: Figure S2), consistent with the results
from mouse tissues (Figures 2 and 3). HIF1α mRNA ex-
pression also responded to KLF5 manipulation and
showed the same trend of expression change as its pro-
tein expression in PC-3 cells (Additional file 3: Figure S2
left panel), in contrast to the result from mouse tissues
where no expression change of HIF1α mRNA was de-
tectable (Figure 2C).
KLF5 loss induces HIF1α protein accumulation by
activating AKT signaling
Following the detection of the angiogenic phenotype and
the activation of the HIF1α-driven pro-angiogenic molecularangiogenic factors. In PC-3 and DU 145 cells with stable knockdown
novirus-mediated overexpression (D) of KLF5, HIF1α protein was de-
-BB and VEGF in the conditioned media were detected by ELISA. shK1
presents siRNA targeting KLF5 (siKLF5), and Ad-K represents adenovirus
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tured human prostate cancer cells, the fundamental
question became how KLF5 loss activates the HIF1α
network to promote angiogenesis. Considering that the
expression change of HIF1α upon KLF5 loss mainly oc-
curred at the protein level but not the mRNA level
(Figures 2, 3 and 5) and that post-transcriptional regu-
lation is the major mechanism of HIF1α regulation [3],Figure 6 KLF5 regulates HIF1α protein via AKT1 kinase. (A, B) Phospho-AKT (
by ectopic expression of KLF5 (B) in PC-3 and DU 145 human prostate cancer
rescued the elevation of HuVEC tube formation and the expression of p-AK
media, collected after 24 hours of 1 μM Wortmannin treatment or solvent
used for HuVEC tube formation assay and detection of PDGF-BB and VEGF
Western blotting. (D) Detection of HIF1α and phospho-AKT (S473) by Western
and treatment of PI3K inhibitor LY294002 for 3 hours. Solvent control for Wor
shRNAs targeting KLF5 (sh36 and sh37), siK represents siRNA targeting KLF5 (si
of siRNA was at 100 nM for panel D. *, P < 0.05; **, P < 0.01; N.S., not statisticalwe focused on the hypothesis that KLF5 loss activates
HIF1α post-transcriptionally.
In our recent study, we found that Klf5 deletion acti-
vates multiple oncogenic signaling pathways including
the PI3K/AKT, ERK and EGF/EGFR pathways [9]. On
the other hand, it has been well established that AKT
and ERK activation leads to the accumulation of HIF1α
mainly by either translational activation or stabilizationS473) is upregulated by the knockdown of KLF5 (A) and downregulated
cells, as detected by Western blotting. (C) Wortmannin, a PI3K inhibitor,
T, HIF1α, PDGF-B and VEGF induced by KLF5 knockdown. Conditioned
control from PC-3 and DU 145 cells with KLF5 knockdown (shK2), were
expression by ELISA. Expression of HIF1α and p-AKT was detected by
blotting in PC-3 and DU 145 cells with transient knockdown of KLF5
tmannin and LY294002 was DMSO. shK1 and shK2 indicate 2 lentiviral
KLF5), and Ad-K represents adenovirus expressing KLF5. The concentration
ly significant.
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induces HIF1α protein accumulation by activating AKT
and ERK signaling. Consistent with the finding from
mouse prostates [9], Western blotting demonstrated that
both stable and transient knockdown of KLF5 in PC-3 and
DU 145 cells increased, and ectopic expression of KLF5
decreased, the expression of activated AKT (p-AKT)
(Figure 6A, B). For both EGFR and ERK, activity changes
were inconsistent between human cancer cell lines and
mouse tissues. Specifically, EGFR activation was slightly
downregulated by both KLF5 knockdown and ectopic ex-
pression in the two cell lines, while ERK activation was
downregulated upon KLF5 ectopic expression only in PC-
3 cells but not in DU 145 cells. ERK activity was un-
changed when KLF5 was knocked down in both the PC-3
and DU 145 cell lines. This result suggests that EGFR and
ERK are less crucial than AKT in mediating the effect of
KLF5 on HIF1α (Additional file 4: Figure S3). Expression
changes of p-AKT (Figure 6A, B) corresponded nicely to
those of HIF1α in the same cells (Figure 5).
To further test whether AKT activation mediates HIF1α
accumulation induced by KLF5 loss, we treated cells with
Wortmannin, an irreversible PI3K/AKT inhibitor. We
found in both PC-3 and DU 145 cells that inhibition of
AKT activity by Wortmannin prevented the enhancement
of tube formation and the upregulation of HIF1α, PDGF-
B and VEGF by KLF5 knockdown (Figure 6C). Similarly,
treatment of PC-3 and DU 145 cells with the LY294002
PI3K inhibitor upon KLF5 transient knockdown also abol-
ished the upregulation of HIF1α protein (Figure 6D).
Discussion
Klf5 loss enhances angiogenesis in prostatic
tumorigenesis
In this study, we performed histological and molecular
analyses in mouse prostate tumors and human prostate
cancer cells with the deletion or knockdown of KLF5
and PTEN, and obtained multiple lines of evidence sug-
gesting the role of KLF5 loss in tumor angiogenesis. First
of all, Klf5 loss enhanced angiogenesis not only during
prostatic tumorigenesis initiated by homozygous dele-
tion of Pten (Figure 1A) but also in mPINs induced by
hemizygous deletion of Pten (Figure 1B), and Klf5’s
homozygous deletion was more potent than its hemizy-
gous deletion in the increase of microvessels (Figure 1).
Secondly, conditioned culture media from human pros-
tate cancer cells with deficient or insufficient PTEN and
KLF5 knockdown increased tube forming capacity and
migration of HuVECs (Figure 4), which are indicative of
angiogenic potential. Overexpression of KLF5 in human
prostate cancer cells showed a consistent effect on
HuVECs (Figure 4). Thirdly, at the molecular level Klf5
deletion significantly elevated the expression of HIF1α
and its pro-angiogenic functional effectors such as VEGFand PDGF (Figures 2, 3 and 5), which represent the
most potent inducers of tumor angiogenesis. Our find-
ings are consistent with a previous study in which Klf5
deletion in mouse corneas enhanced neovascularization
[12], indicating that KLF5 loss in some epithelial tissues
such as prostate and cornea promotes angiogenesis.
While KLF5 loss enhances angiogenesis, the extent of
enhancement may depend on tumorigenesis including
the development of cancer precursors such as mPIN, be-
cause deletion of Klf5 alone, which does not induce neo-
plastic alterations in mouse prostates [30], did not affect
angiogenesis and HIF1α expression (data not shown).
On the other hand, other genetic alterations combined
with Pten deletion more often do not affect angiogenesis
in mouse prostate tumors. For example, overexpression
of COUP-TFII in Pten–null prostates results in aggres-
sive metastasis-prone prostate tumors but does not alter
angiogenesis [31]. In addition, there is no evidence for
alterations in angiogenesis when other tumor suppressor
genes such as p53, Smad4, Nkx3-1 and p27 are deleted
in Pten-null mouse prostates [32-35].
Our recent study showed that interruption of KLF5
acetylation also promotes prostate cancer growth [8].
However, tumor promotion by unacetylated KLF5 does
not appear to affect angiogenesis, as the number of micro-
vessels and the expression of HIF1α and VEGF were not
affected by changes in the acetylation status of KLF5 (data
not shown), and angiogenesis was not among the affected
processes based on bioinformatic analysis [8].KLF5 loss enhances angiogenesis partially by
upregulating HIF1α and its downstream pro-angiogenic
factors including VEGF and PDGF
In understanding how KLF5 loss enhances tumor angio-
genesis, our Gene Ontology (GO) enrichment analysis of
differentially expressed genes upon Klf5 deletion identi-
fied blood morphogenesis as the most affected biological
process, involving a molecular signature of activated
pro-angiogenic genes (Figure 2A). In addition, network
analysis of the differentially expressed genes led to the
identification of HIF1α, a crucial inducer of angiogen-
esis, as a key transcription factor activated by Klf5 dele-
tion, which transcriptionally activated 34 genes upon
Klf5 deletion (Figure 2B). Among the 34 genes, secretory
protein Pdgf-b is a well-established transcriptional target
of HIF1α and a crucial regulator of angiogenesis [2,20]
(Figure 2C). Although VEGF, another key angiogenesis
regulator and secretory protein induced by HIF1α [17],
was not identified by the microarray analysis as being
upregulated by Klf5 deletion, our expression analyses
demonstrated that KLF5 loss indeed upregulated HIF1α
at the protein level and VEGF and PDGF at both the
mRNA and protein levels in both mouse prostate
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or insufficient PTEN (Figure 2, 3 and 5).
In addition to the well-established angiogenesis regula-
tors HIF1α, VEGF and PDGF [36], other molecules
could also be involved in enhanced angiogenesis after
KLF5 loss. For example, Apelin and Adora2b, both of
which are transcriptional targets of HIF1α, were upregu-
lated by Klf5 deletion (Figure 2B) and have been shown
to promote angiogenesis in certain types of cells and ani-
mal models [37,38]. Another group among the 36 genes
that play a role in angiogenesis and were upregulated by
Klf5 deletion in mouse prostates (Figure 2A, Additional
file 1: Table S1) included Il1 and Ang, both encoding
secretory proteins in prostatic epithelial cells that could
also mediate the role of KLF5 loss in angiogenesis.
Upregulation of HIF1α by KLF5 loss is likely mediated by
the activation of PI3K/AKT signaling
HIF1 consists of two subunits, the α unit, which is in-
duced by hypoxia, and the β unit, which is expressed
constitutively [16]. Regulation of HIF1α mainly occurs at
the protein level, since it is degraded by the ubiquitin
proteasome pathway (UPP) under normoxia conditions
but is stabilized under hypoxia conditions in a tumor en-
vironment [2,3]. HIF1α can also be upregulated inde-
pendent of hypoxia upon the activation of growth
factor-dependent signaling pathways [3]. For example,
forced PTEN overexpression reduces HIF1α expression,
whereas activated PI3K/AKT signaling upregulates
HIF1α expression [28,29]. Our recent study established
that Klf5 deletion leads to the activation of PI3K/AKT and
ERK signaling in mouse prostate tumors [9]. Using cul-
tured human prostate cancer cell lines with deficient or
insufficient PTEN, not only did we confirm the activation
of AKT by KLF5 loss (Figure 6A), we also found that acti-
vated AKT indeed mediated the upregulation of HIF1α by
KLF5 loss, since treatment with PI3K inhibitors prevented
both the activation of AKT and the accumulation of
HIF1α (Figure 6C, D). Treatment with PI3K inhibitors
also prevented the enhancement of tube formation by
KLF5 loss (Figure 6C). Therefore, one mechanism for the
upregulation of HIF1α by KLF5 loss in PTEN deficient or
insufficient prostate cancer cells appears to be the activa-
tion of AKT. Previous studies have demonstrated that
PI3K/AKT signaling promotes HIF1α protein accumula-
tion by either increasing its translation or by inhibiting its
degradation or both [25,39,40]. Currently it is unknown
which process is most involved in HIF1α accumulation in-
duced by KLF5 loss and subsequent PI3K/AKT activation.
It is well known that PTEN is a lipid phosphatase
whose loss activates PI3K/AKT signaling [41], which is
related to HIF1α upregulation and enhanced angiogen-
esis in some human cancer cells [42,43]. Our recent
study demonstrated that Klf5 loss in Pten-null prostatetumors also activates PI3K/AKT signaling by upregulat-
ing multiple extracellular growth factors (e.g. EGF), cyto-
kines and their receptors [9]. Deletion of Klf5 alone in
mouse prostates did not affect angiogenesis (data not
shown), and neither did Pten deletion alone in mouse
prostates cause apparent angiogenesis [13]. Therefore,
KLF5 loss and PTEN loss had an additive effect on the
activation of PI3K/AKT signaling [9], HIF1α accumula-
tion (Figure 6), and angiogenesis (Figure 1). The precise
function of KLF5 in mediating AKT activation is still
under investigation.
While two other oncogenic signaling pathways, EGF/
EGFR and ERK, were activated in mouse prostate tu-
mors upon Klf5 deletion [9], and KLF5 could positively
regulate EGFR expression and ERK activation [44,45],
their changes in activity in response to KLF5 modulation
were inconsistent between human prostate cancer cell
lines PC-3 and DU 145 and mouse prostate tissues
(Additional file 4: Figure S3). Therefore, whereas EGFR
and ERK activation may still play a role in the upregula-
tion of HIF1α by Klf5 deletion in mouse prostate tu-
mors, they are less crucial for KLF5 to regulate HIF1α in
human cancer cell lines PC-3 and DU 145.
There are other mechanisms that could account for
how KLF5 regulates HIF1α protein, including transcrip-
tional regulation, miRNA and hypoxia. In colon and
lung cancer cells, KLF5 was shown to directly regulate
the transcription of HIF1α [46,47]. However, our results
(Figure 2 & Additional file 3: Figure S2) showed that
KLF5 did not alter the transcription of HIF1α either in
mouse prostates or in human prostate cancer cells.
HIF1α can also be regulated by miRNAs including miR-
138 [48]. While miR-138 appeared to be downregulated
by Klf5 deletion in mouse prostate tumors, it was un-
altered by KLF5 loss in human prostate cancer cells
(data not shown). Hypoxia is a potent inducer of HIF1α,
but it did not appear to be necessary for KLF5 loss to in-
duce HIF1α, at least in cancer cell lines, because the
morphological and molecular alterations in PC-3 and
DU 145 cells were detected under normoxic conditions
(Figures 4, 5 and 6). Nevertheless, it remains to be clari-
fied whether these additional mechanisms are involved
in the HIF1α accumulation induced by KLF5 loss.
Enhanced angiogenesis by KLF5 loss may partially
account for its tumor promoting function and have
implications in human prostate cancer
Our recent study demonstrated that Klf5 deletion pro-
motes mouse prostate tumorigenesis initiated by Pten de-
letion, as indicated by the accelerated emergence and
progression of mPIN caused by Pten insufficiency and the
more severe morphological and molecular abnormalities
of prostate tumors caused by Pten deficiency [9]. In that
study, enhanced cell proliferation was identified as a
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tion [9]. Our current study suggests that enhanced angio-
genesis by KLF5 loss is likely another mechanism for the
tumor promoting effect of KLF5 loss during prostatic
tumorigenesis initiated by other oncogenic factors, which
is in addition to its previously reported promoting func-
tion in tumor cell proliferation [9].
During the development of human prostate cancer,
chromosome 13q is one of the most frequently deleted
chromosomes, and the deletion involves multiple regions
and genetic foci in 13q14 and 13q21, including RB1 and
FOXO1 at 13q14 and KLF5 at 13q21 [22,49-52]. Whereas
RB1 is a well-established tumor suppressor gene at 13q14,
the tumor suppressor function of KLF5 has also been
demonstrated in both xenograft and knockout models
[7,9]. In addition, conventional comparative genomic
hybridization (CGH) studies indicate that deletion span-
ning the KLF5 locus could occur in as much as 39% of
prostate cancers [6], and our earlier deletion analyses sug-
gest that hemizygous deletion is more common than
homozygous deletion in prostate cancer [22,50]. In the lat-
est genome-wide copy number change studies, KLF5’s deep
deletion, which likely indicates homozygous deletion, has
been detected in 10% of prostate cancers in The Cancer
Genome Atlas (TCGA) database (tcga-data.nci.nih.gov)
and in 20% of metastatic prostate cancers in another data-
base [53], as analyzed by the cBioPortal program [54,55].
Hemizygous deletion induces haploinsufficiency of KLF5
[9,10], and our recent publication demonstrated that
hemizygous deletion of Klf5 in mouse prostates indeed
promotes tumor development [30]. Therefore, frequent
hemizygous and homozygous deletions induce frequent
insufficiency and deficiency, respectively, of KLF5 during
prostatic carcinogenesis. Genetic amplification and over-
expression of the WWP1 E3 ubiquitin ligase, which de-
grades KLF5 protein, also frequently occur in human
prostate cancer [56,57], causing excess protein degrad-
ation and insufficiency of KLF5. Therefore, enhanced
tumor angiogenesis represents another mechanism for
how KLF5 insufficiency and deficiency could promote the
development and progression of human prostate cancer.
As in many other types of cancers, prostatic carcinogen-
esis depends on the accumulation of multiple genetic and
epigenetic alterations, and deletions of KLF5 and PTEN
can occur in the same tumors [22,58-61]. For example, 7
of the 25 (28%) prostate cancers with KLF5 deep deletion
in the TCGA database and 4 of the 11 (36%) metastatic
prostate cancers in another database also have PTEN deep
deletion or truncating mutation [53], as revealed by the
cBioPortal analysis [54,55]. Further related to our current
findings, it has been reported that PTEN inactivation is
positively associated with higher microvessel densities in
clinically localized prostate cancer [43], and PTEN expres-
sion is negatively associated with VEGF expression ingastric carcinomas [62]. Another study demonstrated that
in high-grade prostate adenocarcinomas, 46% of them
showed higher nuclear HIF1α immunostaining, and 89%
expressed higher levels of VEGF [63]. In the context of
concurrent deletions of KLF5 and PTEN in human pros-
tate cancer, our findings further suggest that during the
development of human prostate cancer, KLF5 loss and
PTEN loss cooperate to enhance tumor angiogenesis by
upregulating HIF1α and VEGF, which remains to be
examined.
In summary, we found that deletion of Klf5 promoted
angiogenesis in Pten deletion-initiated mouse prostate
tumors. Promotion of angiogenesis by Klf5 loss involved
the upregulation of pro-angiogenic molecules including
HIF1α and its downstream targets VEGF and PDGF. Up-
regulation of HIF1α was mediated at least in part by the
activation of PI3K/AKT oncogenic signaling. Consist-
ently, knockdown of KLF5 in PTEN-insufficient human
prostate cancer cells increased tube formation and mi-
gration in HuVECs, enhanced PI3K/AKT activity, and
upregulated HIF1α, VEGF and PDGF. These findings in-
dicate that KLF5 loss enhances angiogenesis during
prostatic carcinogenesis initiated by other oncogenic fac-
tors, and that enhanced angiogenesis could be a mech-
anism for the tumor promoting function of KLF5 loss.
Materials and methods
Cell lines, siRNAs, inhibitors and antibodies
Human umbilical vein endothelial cells (HuVECs) were
purchased from Life Technologies and cultured in
Medium 200 with low serum growth supplement (LSGS)
(Carlsbad, CA). PC-3 and DU 145 human prostate can-
cer cell lines and the 293 T human embryonic kidney
cell line were purchased from American Type Culture
Collection (ATCC) (Manassas, VA), and propagated fol-
lowing ATCC’s instructions.
SiRNA against KLF5 (SiKLF5), developed in a previous
study [64] with the sequence of AAGCUCACCUGAGG
ACUCATT, was used to knock down KLF5 in human
cells at a concentration of 150 nM or as indicated in re-
lated figures. The control siRNA (siCtrl), AAUUCUCCGA
ACGUGUCACGUTT, was purchased from Thermo Fisher
(Waltham, MA) used to bring the siRNA concentration to
the same in concentration gradient RNAi assay.
PI3K inhibitors Wortmannin and LY294002 were pur-
chased from Cell Signaling Technology (Danvers, MA),
and dissolved in dimethyl sulfoxide (DMSO).
Antibodies used in this study included the following:
anti-HIF1α and anti-PDGF-B from Novus Biologicals
(Littleton, CO), anti-PDGF-D from Santa Cruz (Santa
Cruz, CA), anti-phospho-AKT (S473), anti-AKT, anti-
phospho-EGFR (Y1068), anti-EGFR, anti-phospho-ERK1/2
and anti-ERK1/2 from Cell Signaling Technology, anti-
VEGF and anti-CD31 from Abcam (Cambridge, MA), and
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been described previously [23].
Mouse prostate tissues with different Klf5 and Pten
deletion status
All mouse prostate tissues with different Klf5 and/or
Pten deletion status, including prostate tumors, mouse
prostatic intraepithelial neoplasia (mPIN) and control
tissues of different ages, were from our recently pub-
lished study [9].
Production of lentiviruses and adenoviruses and their
infection of cells
Lentiviruses expressing KLF5 and shRNA targeting
KLF5 were produced by transfecting respective plasmids
in 293 T cells following the protocols described on the
Addgene website (http://www.addgene.org/lentiviral/
protocols-resources/). The PLKO.1 expression vector
was used for shRNA expression, and the 2 shRNAs tar-
geting KLF5, sh36 and sh37, were described in our previ-
ous study [65]. The pSin expression vector was used for
KLF5 expression (pSin-KLF5) as in our previous study
[66]. Following our previously described procedures
[65], viruses were added to culture media to infect PC-3
and DU 145 cells, and medium containing 1 μg/ml
puromycin was used to select infected cells for at least
96 hours to obtain populations for analysis.
Adenoviruses expressing KLF5 (Ad-KLF5) and GFP
(Ad-GFP) were prepared and used following our estab-
lished procedures [64]. MOI (multiplicity of infection)
was defined as the average number of virus particles in-
fecting a cell.
RNA isolation, real-time RT-PCR and microarray expression
analysis
Mouse dorsal prostates or tumor tissues were dissected
freshly and stored in liquid nitrogen, and total RNA was
isolated by using the RNeasy Mini Kit (Qiagen, Valencia,
CA) following the manufacturer’s instructions. TRIzol
reagent (Life technologies) was used for isolating total
RNA from cultured cellsfollowing previously established
procedures [67]. First-strand cDNA was synthesized
from total RNA using a Promega reverse transcription
kit (Madison, WI).
Real-time RT-PCR was performed using the SYBR Pre-
mix reagent (Takara, Tokyo, Japan) and ABI Fast 7500
Real-time PCR System (Applied Biosystems, South San
Francisco, CA). The 2(−△△Ct) method was used to calcu-
late relative fold changes with GAPDH as the internal
control. Primers used for real-time RT-PCR are listed in
Additional file 5: Table S2.
Genes with significantly different expression between
Klf5 wildtype and Klf5-null 6-month old prostate tumors
in the context of Pten deletion, as described in our recentstudy [9], were uploaded into the web-based MetaCore
platform (http://thomsonreuters.com/metacore/), and
angiogenesis-related genes were enriched using Gene
Ontology (GO)-based functional process enrichment.
Whether a gene functions in angiogenesis was further
evaluated by literature review among PubMed publica-
tions with “angiogenesis” and a gene’s name as key
words. The algorithm of “activated transcription factor
regulating genes in the experimental data” was used to
build a HIF1α-centered network with those that were
not only direct transcriptionally activated targets of
HIF1α but were also upregulated by Klf5 deletion.
Immunohistochemistry (IHC), Western blotting and
enzyme-linked immunosorbent assay (ELISA)
IHC staining was performed following our established
protocols [30] and nuclei were stained with hematoxylin.
Mounted slides were scanned with the Hamamatsu
NanoZoomer scanner (Hamamatsu Corporation, Bridgewater,
NJ) or photographed with a microscope. When needed,
cell numbers were counted by using the ImageJ pro-
gram to calculate the ratio of positive cells for a protein.
Western blotting was performed following our previously
established procedures [68]. For secretory factors, condi-
tioned culture media were collected from 100% confluent
cells in 100-mm dishes, and commercial ELISA kits
against VEGF and PDGF-BB from Abcam were used to
determine the expression level of VEGF and PDGF-BB
following the manufacturer’s instructions.
Tube formation assay in HUVECs
Prostatic epithelial cells were seeded in 100-mm dishes,
grown to 90% confluence at 48 hours, washed with PBS
twice, and then cultured in 3 ml of medium containing
1% serum for another 24 hours to reach 100% conflu-
ence. Conditioned media were then collected, centri-
fuged at 1500 rpm/min, and the supernatant was used
for experiments as previously described [69]. A total of
3 × 104 HuVECs were seeded into each well of a 48-well
plate coated with growth-factor reduced Matrigel (BD
Biosciences, San Jose, CA). After culturing for 5 and
8 hours with conditioned media or the HuVEC culture
medium, the capillary-like structures were captured with
the Olympus IX51 microscope, and the extent of tube
formation was assessed by measuring the cumulative
tube length and counting the number of tube nodes (the
intersection among 3 or more tubes) in a 10× field using
ImageJ software. At least 10 fields were examined to de-
termine cell tube formation ability [70].
Wound healing assay in HuVECs
Confluent monolayer HuVECs cultured in 24-well plates
were scratched with the tip of a 10-μl pipette tip to gener-
ate a cross wound, washed with PBS twice, and cultured
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the gap to close. Photographs of gaps at 0 and 13–15 hours
were taken with an Olympus IX51 inverted microscope at
10× magnification, and the extent of wound closure was
assessed by calculating the ratio of the initial to the final
wound area with Image J software. At least 4 fields were
examined to determine cell migration ability [71].
Transwell migration assay in HuVECs
Five x 104 HuVECs in 200 μl serum-free medium were
seeded in the upper chamber of an insert (BD Biosciences)
in a 24-well plate, and 800 μl of conditioned medium was
added to the lower chamber. After 15–17 hours, cells in
the insert were fixed in 4% paraformaldehyde (Sigma) and
stained with 0.1% crystal violet (Sigma). Cells inside the
transwell chamber were scraped with a cotton swap, while
cells outside the chamber were photographed with an
inverted microscope. The number of cells per field at 4×
magnification was counted with Image J software, and at
least 10 fields were examined to determine cell migration
ability [65].
Statistical analysis
Results from real-time RT-PCR and ELISA were
expressed as means ± standard derivation, while readings
from other experiments were expressed as means ±
standard error. The statistical significance for a differ-
ence between two groups was determined by unpaired
Student t test. A P-value of 0.05 or smaller was consid-
ered statistically significant.
Additional files
Additional file 1: Table S1. Differentially expressed genes involved in
angiogenesis, as identified by the MetaCore program. Fold change between
Klf5-wildtype and Klf5-null groups are shown for each of the genes. P and R
indicate promoting and repressive functions, respectively, of a gene in
angiogenesis.
Additional file 2: Figure S1. Expression changes in KLF5 in PC-3 and DU
145 prostate cancer cells modulate wound healing in HuVECs. Confluent
HuVECs cultured in conditioned media were scratched with a pipette tip
and photographed from 4 fields at 0 and 13-15 hours for each sample.
shK1 and shK2 indicate two shRNAs targeting KLF5 (sh36 and sh37) (A), Ctrl
and KLF5 indicate lentiviruses expressing the pSin vector control and KLF5,
respectively (B). Areas of wound were measured by using ImageJ software
to indicate the extent of wound closure. *, P<0.05; **, P<0.01.
Additional file 3: Figure S2. Modulation of KLF5 expression affects mRNA
expression of pro-angiogenic factors. Real-time RT-PCR was used to detect
mRNA expression of HIF1α, VEGF-A, PDGF-B and PDGF-D mRNA in PC-3 and
DU 145 prostate cancer cells with stable knockdown (A) or ectopic expression
(B) of KLF5. shK1 and shK2 indicate two shRNAs targeting KLF5 (sh36 and
sh37) (A), Ctrl and KLF5 indicate pSin vector control and pSin-KLF5 (B),
respectively. *, P<0.05; **, P<0.01. (TIFF 334 kb)
Additional file 4: Figure S3. EGFR and ERK activation do not appear to
mediate the upregulation of HIF1α by KLF5 knockdown in human prostate
cancer cell lines. Protein expression of p-EGFR (Y1068), EGFR, p-ERK and ERK
were determined by Western blotting in PC-3 and DU 145 cells with stable
knockdown or ectopic expression of KLF5. shK1 and shK2 indicate two shRNAstargeting KLF5 (sh36 and sh37), and Ctrl and KLF5 indicate the pSin vector
control and pSin-KLF5 expression construct, respectively.
Additional file 5: Table S2. Primer sequences used in this study.
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